Evaluation Safety and Explore Efficacy Long-term Follow-up Study on Subjects Receiving SMUP-IA-01 or Active Control
Condition(s) studied
Investigational drug(s) / intervention(s)
SMUP-IA-01(low-dose): A single knee administration of SMUP-IA-01(low-dose, 4.0 x 10\^6 cells/2mL)
SMUP-IA-01(mid-dose): A single knee administration of SMUP-IA-01(mid-dose, 1.0 x 10\^7 cells/2mL)
High Hyal Plus: A single knee administration of Hyaluronic acid(1% Sodium Hyaluronate 20mg/2ml)
Study summary
This is a follow-up study to investigate the long-term safety and explore efficacy of SMUP-IA-01, for the treatment of Knee Osteoarthritis. Subjects who participated in and completed the initial stage of the Phase II trial (NCT05182034) will be followed-up until 60 months.
Eligibility
Primary outcome measure(s)
- Change of total score in WOMAC (Western Ontario and McMaster University) — Time Frame: Month 12, 24, 36, 48 and 60 after treatment
Comparing WOMAC total score changes with baseline scores of SMUP-IA-01 phase I trial and scores of f/u study at 12 months, 24 months, 36 months, 48 months and 60months after treatment (score range 0-96, higher score represent worse symptoms).
Trial sites (5)
| Facility | City | Region | Status |
|---|---|---|---|
| Seoul Nation University Bundang Hospital | Gyeonggi-do | South Korea | |
| Gangnam Severance Hospital | Seoul | South Korea | |
| Korea University Anam Hospita | Seoul | South Korea | |
| Seoul National University Hospital | Seoul | South Korea | |
| Severance Hospital | Seoul | South Korea |
More Medipost Co Ltd. trials in South Korea
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06798727 on ClinicalTrials.gov ↗ ← All trials in South Korea